Dual-Activity Fluoroquinolone-Transportan 10 Conjugates offer alternative Leukemia therapy during Hematopoietic Cell Transplantation - Publication - Bridge of Knowledge

Search

Dual-Activity Fluoroquinolone-Transportan 10 Conjugates offer alternative Leukemia therapy during Hematopoietic Cell Transplantation

Abstract

Hematopoietic cell transplantation (HCT) is often considered a last resort leukemia treatment, fraught with limited success due to microbial infections, a leading cause of mortality in leukemia patients. To address this critical issue, we explored a novel approach by synthesizing antileukemic agents containing antibacterial substances. This innovative strategy involves conjugating fluoroquinolone antibiotics, such as ciprofloxacin (CIP) or levofloxacin (LVX), with the cell-penetrating peptide (CPP) transportan 10 (TP10). Here, we demonstrate that the resultant compounds display promising biological activities in preclinical studies. These novel conjugates not only exhibit potent antimicrobial effects but are also selective against leukemia cells. The cytotoxic mechanism involves rapid disruption of cell membrane asymmetry leading to membrane damage. Importantly, these conjugates penetrated mammalian cells, accumulating within the nuclear membrane without significant effect on cellular architecture or mitochondrial function. Molecular simulations elucidated the aggregation tendencies of TP10 conjugates within lipid bilayers, resulting in membrane disruption and permeabilization. Moreover, mass spectrometry analysis confirmed efficient reduction of disulfide bonds within TP10 conjugates, facilitating release and activation of the fluoroquinolone derivatives. Intriguingly, these compounds inhibited human topoisomerases, setting them apart from traditional fluoroquinolones. Remarkably, TP10 conjugates generated lower intracellular levels of reactive oxygen species (ROS) compared to CIP and LVX. The combination of antibacterial and antileukemic properties, coupled with selective cytostatic effects and minimal toxicity towards healthy cells, positions TP10 derivatives as promising candidates for innovative therapeutic approaches in the context of antileukemic HCT. This study highlights their potential in search of more effective leukemia treatments.

Citations

  • 2

    CrossRef

  • 0

    Web of Science

  • 1

    Scopus

Cite as

Full text

full text is not available in portal

Keywords

Details

Category:
Articles
Type:
artykuły w czasopismach
Published in:
MOLECULAR PHARMACOLOGY no. 105, pages 39 - 53,
ISSN: 0026-895X
Language:
English
Publication year:
2024
Bibliographic description:
Lica J., Heldt M., Wieczór M., Chodnicki P., Ptaszyńska N., Łęgowska A., Brankiewicz W., Gucwa K., Stupak A., Maciejewska N., Pradhan B., Gitlin-Domagalska A., Dębowski D., Milewski S., Bieniaszewska M., Grabe G. J., Hellmann A., Krzysztof R.: Dual-Activity Fluoroquinolone-Transportan 10 Conjugates offer alternative Leukemia therapy during Hematopoietic Cell Transplantation// MOLECULAR PHARMACOLOGY -,iss. 05 (1) (2024), s.39-53
DOI:
Digital Object Identifier (open in new tab) 10.1124/molpharm.123.000735
Sources of funding:
  • The financial support to maintenance of research facilities used in these studies from Gdańsk University of Technology by the DEC--2/2021/IDUB/V.6/Si grant under the SILICIUM SUPPORTING CORE R&D FACILITIES – “Excellence Initiative - Research University”
Verified by:
Gdańsk University of Technology

seen 114 times

Recommended for you

Meta Tags